Does GM-CSF Restore Neutrophil Phagocytosis in Critical Illness?

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

February 28, 2015

Conditions
Critical IllnessSepsisImmuno-suppression
Interventions
DRUG

Leukine

Daily subcutaneous injection of either 3 or 6 micrograms per kilo per day, for either 4 or 7 days.

DRUG

Normal Saline

Patients in the randomised controlled trial may receive this placebo as a single daily subcutaneous injection. The volume will match that of the active drug.

Trial Locations (4)

NE9 6SX

Queen Elizabeth Hospital, Gateshead

NE1 4LP

Royal Victoria Infirmary, Newcastle upon Tyne

NE7 7DN

Freeman Hospital, Newcastle upon Tyne

Unknown

Sunderland Royal Hospital, Sunderland

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medical Research Council

OTHER_GOV

collaborator

Newcastle University

OTHER

lead

Newcastle-upon-Tyne Hospitals NHS Trust

OTHER